Disease Markers

Research Article

Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis

Table 2

Change in EASI and relative values of the eight metabolites at baseline and 16 weeks in the 19 patients.


Patient	Change in EASI (%)	Lactic acid		Alanine		Glyceric acid		Fumaric acid		Nonanoic acid		Ribose		Sorbitol		Ornithine
Patient	Change in EASI (%)	Base line	16w	Base line	16w	Base line	16w	Base line	16w	Base line	16w	Base line	16w	Base line	16w	Base line	16w

1	−89	2.4889	2.9917	0.6746	0.9216	0.0664	0.0599	0.0079	0.0074	0.0927	0.1035	0.0572	0.1049	0.0159	0.0170	1.0434	1.3224
2	−93	3.8149	3.3289	0.8477	0.6685	0.0509	0.0565	0.0047	0.0055	0.0976	0.0848	0.0438	0.0568	0.0092	0.0086	0.8581	0.8845
3	−79	1.9904	4.0866	0.5142	0.9825	0.0570	0.0642	0.0090	0.0139	0.0746	0.0951	0.0553	0.0334	0.0112	0.0161	1.0689	1.8425
4	−89	4.6248	3.5115	0.6509	0.6761	0.0723	0.0678	0.0106	0.0067	0.0897	0.0831	0.0744	0.0619	0.0071	0.0084	1.0829	1.3529
5	−79	4.7877	3.5567	0.5143	0.6977	0.0808	0.0692	0.0105	0.0077	0.1063	0.1263	0.0750	0.0815	0.0153	0.0324	0.6537	1.3012
6	−94	3.8781	4.3780	0.9444	0.9464	0.0627	0.0672	0.0065	0.0053	0.0805	0.1092	0.0637	0.0084	0.0094	0.0115	1.3627	1.7566
7	−85	3.5302	3.7355	0.8714	0.9678	0.0555	0.0636	0.0086	0.0077	0.1095	0.1033	0.0847	0.0651	0.0131	0.0139	1.5498	1.6364
8	−80	3.8297	4.5453	0.9633	0.9685	0.0734	0.0709	0.0085	0.0063	0.1003	0.0997	0.0868	0.0146	0.0177	0.0195	0.9360	1.1365
9	−90	3.7840	4.9297	0.8221	1.2222	0.0619	0.0730	0.0085	0.0096	0.1341	0.1136	0.0286	0.0318	0.0186	0.0099	0.8834	0.9960
10	−92	3.2407	3.1664	0.7450	0.9131	0.0530	0.0565	0.0091	0.0061	0.0950	0.1343	0.0604	0.0339	0.0106	0.0197	1.0975	1.1890
11	−86	4.5377	3.0263	0.6812	0.6232	0.0669	0.0559	0.0120	0.0084	0.1148	0.1111	0.0157	0.0237	0.0173	0.0151	1.4908	1.4761
12	−63	7.6957	5.2954	0.7900	0.9215	0.0795	0.0839	0.0098	0.0078	0.1133	0.1098	0.0300	0.0222	0.0395	0.0108	0.7932	1.8137
13	−52	3.2983	2.3237	0.9511	0.6386	0.0587	0.0567	0.0087	0.0068	0.1168	0.1058	0.0485	0.0232	0.0231	0.0127	1.4648	1.9583
14	−64	6.6554	4.8795	1.2550	1.1480	0.0880	0.0809	0.0144	0.0109	0.1170	0.1079	0.0099	0.0061	0.0292	0.0385	2.4528	2.4301
15	−71	5.8131	2.3452	0.9683	0.7496	0.0826	0.0564	0.0110	0.0078	0.1221	0.1089	0.0070	0.0284	0.0226	0.0081	1.2126	1.2907
16	−65	4.0100	2.9432	0.9355	0.7461	0.0642	0.0641	0.0123	0.0089	0.1154	0.1109	0.0155	0.0306	0.0131	0.0091	1.7498	1.3237
17	−70	5.6049	6.2525	1.1042	1.1011	0.0842	0.0784	0.0136	0.0126	0.1266	0.1072	0.0060	0.0170	0.0300	0.0645	3.2616	2.8630
18	−42	3.5198	5.0150	1.0969	0.8776	0.0642	0.0708	0.0076	0.0089	0.1266	0.1062	0.0214	0.0100	0.0089	0.0106	1.3697	1.8835
19	−53	4.7706	4.3064	0.9184	1.1074	0.0732	0.0632	0.0104	0.0077	0.1182	0.1331	0.0229	0.0328	0.0188	0.0089	1.5304	1.6858

Note. The patients Nos. 1–11 and 12–19 were categorised high responders (HR) and low responders (LR), respectively, based on the percent change in EASI at 16 weeks from baseline. The relative values of the eight metabolites were calculated at baseline and 16 weeks by metabolome analysis for the 19 patients. EASI: Eczema Area and Severity Index.